Efficacy of mulberry, red ginseng and banaba in the regulation of blood glucose and insulin responses in type 2 diabetes

A six-month supplementation of mulberry, Korean red ginseng and banaba decreases biomarkers of systemic low grade inflammation in subjects with impaired glucose tolerance and type 2 diabetes

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12611000655943

Enrollment

Registered

2011-06-27

Start date

2007-03-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

To evaluate the long-term efficacy and safety of traditionally used anti-diabetic herbs in controlling blood glucose homeostasis and low grade inflammation, a six month clinical trial was performed with red ginseng roots, mulberry leaf water extract, and banaba leaf water extract in subjects with impaired glucose tolerance or mild cases of T2D.

Interventions

6g/day (2g x 3 times a day) of 1:1:1 mixture of the herbal preparation for 24 weeks. (6g/day of herabl preparation was consisted of 2g/day of Korean red ginseng, 2g/day of Muberry leaf, 2g/day of banaba leaf) Speficification of herbal preparation: Korean red ginseng (Panax ginseng C.A. Mayer) powder, mulberry (Morus alba L.) leaf water extract powder, and banaba (Lagerstroemia speciosa L.) leaf water extract powder The mode of administration: oral capsule

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

35 Years to 79 Years

Healthy volunteers

Inclusion criteria

1) Subjects diagnosed with the impaired glucose tolerence 2) Subjects diagnosed with type 2 diabetes taking one or the combination of following mediations and have not changed the prescription for at least two months. Mediations: sulfonylurea, biguanide, alpha-gludosidase 3) Subjects with BMI over 20kg/m2, non-pregnant who has not taken herbs at least for last 3 months

Exclusion criteria

1) Patients taking insulin or medications other than sulfonylurea, biguanide or alpha-glucosidase during last 2 months 2)Individuals with chronic liver diseases, advanced kidney di se ases, atherosclerosis, myocardial infarction, pulmonary diseases, gastrointestinal diseases, hematological diseases and cancer 3) Individuals receiving or have received pharmacological doses of steroids and/or participating weight reduction programs

Outcome results